Hirsutism future or investigational therapies: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hirsutism}} | {{Hirsutism}} | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}}{{RHN}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
Revision as of 15:11, 20 September 2017
|
Hirsutism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Hirsutism future or investigational therapies On the Web |
|
Directions to Hospitals Treating Hirsutism future or investigational therapies |
|
Risk calculators and risk factors for Hirsutism future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Rasam Hajiannasab M.D.[2]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Future or Investigational Therapies
Fluridil (2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl) phenyl]-3-(2,2,2-trifluoroacetylamino)ropanamide) is a new topical antiandrogen agent and has been developed for hyperandrogenic skin syndromes.
A clinical study has shown that a 2% fluridil gel is a safe and effective treatment method of hirsutism and also has no effect on libido or sexual function but Fluridil is not available yet.[1]